Rebrand Opportunity The company recently rebranded to Precision for Medicine, Oncology and Rare Disease through a merger with Agility Clinical, signaling expanded capabilities and global scale. This presents a sales opening to align current or prospective clients with the broader Precision for Medicine suite, particularly in rare disease and rare cancer programs.

Rare Disease Focus Emphasize capabilities in rare disease and rare cancers as a differentiator. The expanded focus suggests a need for end-to-end CRO services and specialized trial support, offering opportunities to position integrated services across study design, execution, data management, and regulatory readiness.

Mid Market Scale With a workforce size in the mid to large range and revenue in the low tens of millions, target mid-sized biopharma and biotech firms seeking a scalable CRO partner capable of handling complex trials without the overhead of larger mega-CROs.

Cross-Sell Potential The union implies a broader capabilities footprint across multiple therapeutic areas. Use opportunities to cross-sell adjacent services such as oncology trial operations, translational science, and global feasibility to existing Agility Clinical or Precision for Medicine prospects.

Digital & Global Reach Leverage the global scale and technology stack mentioned (data visualization, charting, outreach tools) to position a data-informed, tech-enabled trial operation model. Highlight capabilities in streamlined virtual monitoring, analytics, and reporting to appeal to sponsors seeking efficiency and transparency.